The impact of this work is that it demonstrates for the first time that TSLP levels in the lungs of children with asthma are linked to clinical severity and thus provides needed support to investigate the potential use of anti-TSLP or other biologics targeting type 2 inflammation in the pediatric population. This evidence concerns the gene TSLP and asthma.